Cullinan Management

Cullinan Management

Developer of an externally sourced cancer therapeutics used to end a drug program quickly

Company website
Foundation year

2017

Close date

2/7/2021

Profitability

72.33%

About

Total Funding 

$389.7M


Cullinan Oncology is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.


Number of employees

11-50


Headquarters

Cambridge, Massachusetts, United States


2022 © All rights reserved

You can always come to our office to discuss any questions with our manager

Dubai

Sharjah Media City, Sharjah, UAE

USA

500 Delaware ave,
STE 1 #1960 Wilmington, DE, USA

Czech Republic

Czech Republic, Prague, Bilkova 855/19

The investment opportunities posted on this website's Pre-IPO section are private placements of securities that are not traded on the open market, subject to the ownership period requirements, and intended for investors who do not require liquid investments. Investments in private companies may be considered speculative, involving high risk, including the significant loss of investment risk. Investors must be able to afford to lose all their investments.